NCI CLARITY Study
Overall Goal: To build an NCI Intramural Research Program (IRP)-based collaborative translational science network of liver cancer clinical trial data, accompanying biospecimens and correlative laboratory data.
Specific Aim: Determine why immunotherapy is effective in certain patients but not in others and to use this information to develop novel therapies.
Background: Primary liver cancer (PLC) is the 2nd most common cause of cancer-related death worldwide and the one cancers with the fastest rising incidence and mortality in the U.S. PLC consists of two main histological subtypes, i.e., hepatocellular carcinoma (HCC) and cholangiocarcinoma (CCA). PLC is clinically and biologically heterogeneous which has impeded biological assessment and clinical treatment. Despite considerable efforts towards improving diagnosis and development of new treatment modalities, the improvement of PLC patient survival is minimal. PLC therefore remains among the most difficult-to-treat malignancies, with a 5-year survival rate of less than 15% in the United States. Thus, it is imperative that new treatment modalities are developed to limit cancer development and treat advanced PLC.
Study Focus: Immunotherapy is a promising new approach in PLC treatment. At the moment, it is difficult to determine which patient may benefit from immunotherapy, due in large part to the lack of large comprehensive studies, biobank resources of specimens and biospecimen collection in clinical trial protocols, which deter our ability to understand and define critical genomic or genetic factors that contribute to patient response.
Study Objectives: We will collect PLC patient specimens and clinical data from those undergoing immunotherapies at NIH Clinical Center and clinical sites across the U.S. to develop predictors for (a) response or resistance to immunotherapy and (b) acquired resistance to immunotherapy.
Study Information and Design
- Acronym: NCI CLARITY: Cancers of the Liver: Accelerating Research of Immunotherapy by a TransdisciplinarY Network (Note: The study aims to provide ‘clarity’ on who responds/does not respond to immunotherapy.)
- Protocol#: 20-C-006 (on NIH clinical trials.gov); patients should be enrolled on an immunotherapy trial at NIH CRC or at a participating site and will dually enroll on this natural history (observational) study; 5-year study; estimated enrollment: 500 individuals.
- Includes the two main forms of primary human liver cancer: HCC and CCA.
- Large multi-institutional and multidisciplinary study involving collaboration between NCI and several domestic clinical institutions. This is rare for this type of cancer.
- A biorepository of multiple human biospecimens (tissue biopsy, blood, urine and stool) longitudinally collected (baseline, on treatment, post treatment and follow-up) for multiple downstream correlative studies including large-scale genomics.
- Identify patient subgroups, biomarkers and/or molecular signatures associated with immunotherapy response.
Specimen Collection and Correlative Studies at NCI
Primary liver cancer IO patients will be enrolled at clinical sites where biospecimens and medical data will be collected and sent to NCI. At NCI, biospecimens will be processed for respective correlative studies performed by NCI Investigators and will be integrated with bioinformatic approaches.
The clinical portion of the study is on the left (green) while the research portion is on the right (blue). Please note that BPC stands for Biospecimen Processing Core.
NCI CLARITY Study Team
Extramural Pathology Lead
Extramural Radiology Lead
Intramural Research Staff
Erica Pehrsson, Ph.D. – Bioinformatician
TBD – Data Manager
TBD – Technician
Intramural Clinical Staff
Elizabeth Akoth – Research Nurse
Santhana Webb – Research Nurse
Angelicia Garrison – Patient Care Coordinator
Grace-Ann Fasaye – Genetic Counselor
Anuradha Budhu, Ph.D.
Program Manager, NCI CCR Liver Cancer Program
Senior Associate Scientist, Liver Carcinogenesis Section
Laboratory of Human Carcinogenesis
NCI Center for Cancer Research